What bit bio does
A spin-out from the University of Cambridge, bit bio develops proprietary technologies for the efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy.
The company, formed in 2016 as Elpis Biomed, has built a gene engineering approach known as opti-ox (optimised inducible over-expression), which enables precise reprogramming of entire cultures of stem cells into any desired cell type.
Chief executive Mark Kotter says that cell therapy has potential in the treatment of cancer, but that research is being slowed by the limited availability of human cells to test on.
bit bio is hoping to build a scalable platform technology capable of producing any human cell type in order to meet the growing research need for access to human cells.
Developing the future
Last year, the company unveiled a new executive team, following its rebranding from Elpis Biomed.
The biotech is now headed by chief executive Mark Kotter, a stem cell biologist and neurosurgeon at the University of Cambridge, while Florian Schuster, the former finance boss of Tessa Therapeutics, is taking up the positions of chief financial and chief operations officer.
The firm’s chief business officer, meanwhile, is Paul Morrill, the co-founder of gene editing firm Horizon Discovery Group PLC (LON:HZD), with immune-oncology clinician Ramy Ibrahim and stem cell reprogramming specialist Marius Wernig serving as scientific advisors.
How it is doing
In February, bit bio signed an agreement with AIM-listed reagent distributor Abcam to make its iPSC derived functional human cells available to the global life science community.
The first product available will be brain cells for the neuroscience community.